Shanghai yingli pharmaceutical
Webb6 apr. 2024 · YY-20394: Shanghai YingLi Pharmaceutical Co. Ltd. Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products Drug profiles in the detailed report….. Inactive Products Peripheral T-Cell Lymphomas (PTCL) Key Companies Peripheral T-Cell Lymphomas (PTCL) Key Products Peripheral T-Cell Lymphomas (PTCL)- Unmet … Webb1 mars 2024 · Shanghai Yingli Pharmaceutical overview. Shanghai Yingli Pharmaceutical (Yingli) is a pharmaceutical company focused on discovery and development of …
Shanghai yingli pharmaceutical
Did you know?
Webb9 feb. 2024 · Established in 2011, Shanghai Yingli Pharma is a small-molecule innovation drug research and development company rooted in China and with a global vision. The … Webb11 juni 2024 · Yingli Pharma, headquartered in Shanghai with a subsidiary in San Francisco, is an innovative clinical stage biopharmaceutical company. Yingli Pharma is …
Webb15 nov. 2024 · Introduction Peripheral T cell lymphoma (PTCL) is an aggressive tumor type with poor survival, where treatment options for relapsed and/or refractory (r/r) disease are very limited. Standard treatments have a median progression free survival (PFS) of only 3-4 months. The novel PI3Kd-selective inhibitor, linperlisib (YY-20394), has indicated a … WebbClinical Trials Sponsored by Shanghai YingLi Pharmaceutical Co. Ltd. Total 16 results. NCT05457517 Recruiting A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors. Advanced …
Webb17 juni 2024 · Sponsor: Shanghai Yingli Pharmaceutical. EA – previously submitted to ASCO 2024. The research was funded by: Shanghai Yingli Pharmaceutical Co., Ltd Keywords: Molecular Targeted Therapies Conflicts of interests pertinent to the abstract H. Bao Employment or leadership position: Chief medical officer Z. Xu WebbShanghai Yingli Pharmaceutical overview. Shanghai Yingli Pharmaceutical (Yingli) is a pharmaceutical company focused on discovery and development of innovative small …
Webb28 feb. 2024 · At a glance Originator Shanghai Yingli Pharmaceutical Developer Jiangsu Hengrui Medicine Co.; Shanghai Yingli Pharmaceutical Class Antineoplastics; Morpholines; Piperidines; Pyridines; Quinazolines; Small molecules; Sulfonamides Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors Orphan Drug Status
WebbShanghai Yingli Pharmaceutical Co Ltd is a company that operates in the Pharmaceuticals industry. It employs 6-10 people and has $1M-$5M of revenue. The company is … dyd furniture incWebbFebruary 03, 2024. The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: A phase 2, single-arm, open-label clinical trial (Clin Cancer Res) - P2 N=123 NCT04370405 "The ORR of 84 FAS patients was 79.8% (95%CI: 69.6-87.8, 67 patients), with 13 patients (15.5%) achieving a complete ... dyder sweetheartWebbShanghai YingLi Pharmaceutical Co. Ltd. 2024-09-30 Phase 1 A Single-Arm, Open-Label, Multi-Center, Phase I Study of YY-20394 in Patients With Recurrent or Refractory Peripheral T-Cell Lymphoma crystal palace shirt historyWebbShanghai Yingli Pharmaceutical Co Ltd is a company that operates in the Pharmaceuticals industry. It employs 6-10 people and has $1M-$5M of revenue. The company is headquartered in Shanghai, Shanghai, China. Read More Contact Who is Shanghai Yingli Pharmaceutical Headquarters crystal palace signed shirtWebbShanghai YingLi Pharmaceutical Co. Ltd. 2024-05-07 Phase 2 A Phase 2, Single Arm, Open Label Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of … dydd rhyngwladol y merchedWebb11 juni 2024 · Yingli Pharma, headquartered in Shanghai with a subsidiary in San Francisco, is an innovative clinical stage biopharmaceutical company. Yingli Pharma is developing best-in-class and... crystal palace silver membershipWebb28 juni 2024 · 企查查为您提供上海康景生物医药科技有限公司的最新工商信息、公司简介、公司地址、电话号码、招聘信息、信用信息、财务信息、法律诉讼等多维度详细信息查询,让您对上海康景生物医药科技有限公司能够做到全面的了解! crystal palace signings transfermarkt